Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Wedbush boosted their Q3 2025 earnings per share estimates for Apellis Pharmaceuticals in a research report issued on Tuesday, July 1st. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $1.35 for the quarter, up from their prior estimate of ($0.41). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at $0.20 EPS.

Several other analysts have also issued reports on APLS. Morgan Stanley boosted their target price on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday. Citigroup lowered their target price on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 22nd. Robert W. Baird lowered their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Mizuho lowered their target price on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Finally, Scotiabank lowered their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.79.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, reaching $17.99. 891,120 shares of the company's stock were exchanged, compared to its average volume of 2,351,659. The business's fifty day simple moving average is $18.15 and its 200 day simple moving average is $23.52. The firm has a market capitalization of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67. Apellis Pharmaceuticals has a one year low of $16.10 and a one year high of $42.47. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The business had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The business's revenue was down 3.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.54) earnings per share.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the transaction, the general counsel directly owned 133,730 shares in the company, valued at $2,510,112.10. The trade was a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. US Bancorp DE grew its position in Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Apellis Pharmaceuticals by 2.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 115,045 shares of the company's stock worth $3,671,000 after purchasing an additional 2,250 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 4.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 996,748 shares of the company's stock worth $31,806,000 after purchasing an additional 40,386 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 36.5% in the 4th quarter. Victory Capital Management Inc. now owns 562,269 shares of the company's stock worth $17,942,000 after purchasing an additional 150,363 shares in the last quarter. Finally, M&T Bank Corp purchased a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth about $216,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).